Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.

Blockhead10-21 22:50

Shares of Korro Bio (KRRO) and Wave Life Sciences (WVE) sank Monday after an analyst argued the former is the better way to play the RNA-editing space. ↑ X How To Buy Stocks: 4 Factors For ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477860906?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/11/Stock-drugVials-01-adobe-150x150.jpg","is_english":true,"pubTime":"2024-10-21 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477860906","market":"us","top_or_hot":-1,"title":"Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.","media":"Blockhead","content":"<div>\n<p>Shares of Korro Bio (KRRO) and Wave Life Sciences (WVE) sank Monday after an analyst argued the former is the better way to play the RNA-editing space.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: 4 Factors For ...</p>\n\n<a href=\"https://www.investors.com/news/technology/korro-bio-wave-life-sciences-rna-editing/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-21 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/korro-bio-wave-life-sciences-rna-editing/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Korro Bio (KRRO) and Wave Life Sciences (WVE) sank Monday after an analyst argued the former is the better way to play the RNA-editing space.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: 4 Factors For ...</p>\n\n<a href=\"https://www.investors.com/news/technology/korro-bio-wave-life-sciences-rna-editing/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://www.investors.com/news/technology/korro-bio-wave-life-sciences-rna-editing/","article_id":"2477860906","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/11/Stock-drugVials-01-adobe-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477860906","pubTimestamp":1729522237,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓","KRRO":"Korro Bio, Inc.","RNA":"Avidity Biosciences, Inc.","WVE":"Wave Life Sciences Pte. Ltd","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","GSK":"葛兰素史克","BK4588":"碎股","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"Korro Bio在RNA编辑方面落后于Wave Life Sciences。为什么它最终会引领这个领域。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1,"KRRO":1,"RNA":1,"WVE":1,"GSK.UK":0.6},"content_text":"Shares of Korro Bio (KRRO) and Wave Life Sciences (WVE) sank Monday after an analyst argued the former is the better way to play the RNA-editing space.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: 4 Factors For Finding Quality Trade Ideas\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: 4 Factors For Finding Quality Trade Ideas\n\n\n\n\nRBC Capital Markets analyst Luca Issi's view follows results from Wave last week in two patients with alpha-1 antitrypsin disease, or AATD. In this condition, patients don't make any of the AAT protein which helps protect the lungs from damage. After a single dose of Wave's RNA-editing drug — which is partnered with GSK — both patients began making that protein for the first time.\nThe news proves the theory that RNA editing can work in humans, Issi said. And that's a boon for the entire field.\n\"Overall, while we acknowledge WVE is ahead, we continue to believe that KRRO is the better way to play RNA editing given unconstrained economics (vs. mostly GSK (GSK) for WVE) and still about one-third of the enterprise value (of the company on Wall Street) despite the most last week,\" he said in a report.\nIn morning trades on today's stock market, Korro Bio stock fell more than 3% to 77.19, reversing an earlier rise, while shares of Wave Life Sciences slipped more than 3% to 14.84.\nWhy Korro Bio Could Be A Better Play\nIssi expects Wave to unveil additional details at its investor day on Oct. 30. So far, the results are from two patients, both of whom have two copies of the affected gene in AATD. He expects to see baseline characteristics of both as well as details of how quickly their bodies generated the missing AAT protein.\nKorro Bio \"thinks that WVE's data is fantastic news for the broader field, as the bear thesis (drugging ADAR won't work in humans) is officially off the table,\" he said following a meeting with Korro's management. ADAR, or adenosine deaminases acting on RNA, is the specific target of Wave Life Sciences' editing.\nBut there are some key differences between Korro's and Wave's approach. Korro Bio's drug uses an intravenous infusion. This is more cumbersome than Wave's under-the-skin injection, but it could drive higher protein levels, he said.\nFurther, Korro Bio owns its entire program, while most of the economics from Wave Life Sciences' efforts will ultimately go to partner GSK.\nKorro expects to unveil initial clinical proof-of-concept data next year, he said. Issi raised his price target on Korro Bio to 105 from 95, and on Wave Life Sciences to 17 from 15. He has an outperform rating on the former and a sector perform rating on the latter.\n\"We are impressed by recent execution across three programs (from Wave Life Sciences), but with RNA editing likely to be the primary focus of investors going forward, we believe KRRO is the better way to play the space,\" he said.\nBoth Top 1% Stocks\nIBD Digital shows high ratings for both Korro Bio and Wave Life Sciences stocks. The duo has perfect Relative Strength Ratings of 99, which means they outrank 99% of all stocks in terms of 12-month performance.\nWave stock broke out of a lengthy consolidation with a buy point at 6.63 on its news last week.\nSimilarly, Korro shares leapfrogged their 200-day moving average, MarketSurge shows.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nGet Timely Buy & Sell Alerts With IBD Leaderboard\nBest Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477860906"}